MOTS-c research: studies, doses and safety

A peptide the body makes; injection benefits and safety remain unproven.

Also called: MOTS-C, Mitochondrial open reading frame of the 12S rRNA-c.

Mitochondrial-derived peptides · 16-amino-acid mitochondrial signaling peptide.

Endogenous biomarker measurements, registrations without results and administration of the CB4211 analogue do not establish direct human MOTS-c results. A direct-administration evidence level is not established here.

Key studies

  • Kidney failure and stress signals: Circulating mitochondrial peptides were lower in kidney failure; MOTS-c was inversely linked to the AGE/sRAGE ratio. (source)
  • Exercise in cerebral palsy: Natural peptide levels were similar at rest; a 45-minute run caused no or modest changes across groups. (source)
  • Hashimoto's thyroiditis: MOTS-c was lower in Hashimoto's thyroiditis, p<0.001. Levothyroxine use was not linked to different levels. (source)
  • Atrial fibrillation biomarkers: Atrial tissue humanin and MOTS-c were lower in atrial fibrillation; plasma MOTS-c was also lower. (source)
  • Kidney transplant biomarkers: Median MOTS-c was 178 vs 142 ng/mL, p=0.014. It was not significantly linked to cardiovascular disease or mortality. (source)
  • Dialysis and arterial stiffness: Urinary MOTS-c correlated with arterial stiffness, r=0.708, p=0.001; dialysate MOTS-c correlated inversely, r=-0.717, p=0.019. (source)

Related to MOTS-c

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.